These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31685557)

  • 1. Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors.
    Coosemans A; Baert T; Ceusters J; Busschaert P; Landolfo C; Verschuere T; Van Rompuy AS; Vanderstichele A; Froyman W; Neven P; Van Calster B; Vergote I; Timmerman D
    Int J Gynecol Cancer; 2019 Nov; 29(9):1381-1388. PubMed ID: 31685557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
    Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
    Front Immunol; 2019; 10():1273. PubMed ID: 31214202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Relevance and Immunosuppressive Pattern of Circulating and Infiltrating Subsets of Myeloid-Derived Suppressor Cells (MDSCs) in Epithelial Ovarian Cancer.
    Okła K; Czerwonka A; Wawruszak A; Bobiński M; Bilska M; Tarkowski R; Bednarek W; Wertel I; Kotarski J
    Front Immunol; 2019; 10():691. PubMed ID: 31001284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-Associated Macrophages and Myeloid-Derived Suppressor Cells as Immunosuppressive Mechanism in Ovarian Cancer Patients: Progress and Challenges.
    Okła K; Wertel I; Polak G; Surówka J; Wawruszak A; Kotarski J
    Int Rev Immunol; 2016 Sep; 35(5):372-385. PubMed ID: 27644763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal neutrophils activated by KRAS-induced ovarian cancer exert antitumor effects by modulating adaptive immunity.
    Yoshida M; Taguchi A; Kawana K; Ogishima J; Adachi K; Kawata A; Nakamura H; Sato M; Fujimoto A; Inoue T; Tomio K; Mori M; Nagamatsu T; Arimoto T; Koga K; Hiraike OW; Oda K; Kiyono T; Osuga Y; Fujii T
    Int J Oncol; 2018 Oct; 53(4):1580-1590. PubMed ID: 30066851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell rehab: new strategies to unleash therapeutic immunity in ovarian cancer.
    Chae CS; Teran-Cabanillas E; Cubillos-Ruiz JR
    Cancer Immunol Immunother; 2017 Aug; 66(8):969-977. PubMed ID: 28214928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myeloid-Derived Suppressor Cells Mediate Immunosuppression After Cardiopulmonary Bypass.
    Hübner M; Tomasi R; Effinger D; Wu T; Klein G; Bender M; Kilger E; Juchem G; Schwedhelm E; Kreth S
    Crit Care Med; 2019 Aug; 47(8):e700-e709. PubMed ID: 31149961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantification of Early-Stage Myeloid-Derived Suppressor Cells in Cancer Requires Excluding Basophils.
    Khan ANH; Emmons TR; Wong JT; Alqassim E; Singel KL; Mark J; Smith BE; Tario JD; Eng KH; Moysich KB; Odunsi K; Abrams SI; Segal BH
    Cancer Immunol Res; 2020 Jun; 8(6):819-828. PubMed ID: 32238380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
    Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
    J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myeloid-derived suppressor cells and their role in gynecological malignancies.
    Mabuchi S; Yokoi E; Komura N; Kimura T
    Tumour Biol; 2018 Jul; 40(7):1010428318776485. PubMed ID: 30074452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic effects of tumor infiltrating regulatory T cells and myeloid derived suppressor cells assessed by multicolor flow cytometry in gastric cancer patients.
    Choi HS; Ha SY; Kim HM; Ahn SM; Kang MS; Kim KM; Choi MG; Lee JH; Sohn TS; Bae JM; Kim S; Kang ES
    Oncotarget; 2016 Feb; 7(7):7940-51. PubMed ID: 26799288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells.
    Soong RS; Anchoori RK; Yang B; Yang A; Tseng SH; He L; Tsai YC; Roden RB; Hung CF
    Oncotarget; 2016 Oct; 7(42):68489-68502. PubMed ID: 27655678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The expression and association of CD14(+) HLA-DR(Low/-) myeloid-derived suppressor cell-like cells and interleukin-1β in ovarian cancer].
    Wang HY; Zhao R; Ren H; Zou MJ; Zhang J; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2663-2669. PubMed ID: 28910953
    [No Abstract]   [Full Text] [Related]  

  • 14. (3R)-5,6,7-trihydroxy-3-isopropyl-3-methylisochroman-1-one enhanced the therapeutic efficacy of anti-PD1 antibody through inhibiting PI3Kδ/γ.
    Cao L; Dai C; Qin R; Guo Y; Liu J
    Immunopharmacol Immunotoxicol; 2019 Dec; 41(6):599-606. PubMed ID: 31691624
    [No Abstract]   [Full Text] [Related]  

  • 15. Myeloid-Derived Suppressor Cells in Cancers and Inflammatory Diseases: Angel or Demon?
    Su Z; Ni P; Zhou C; Wang J
    Scand J Immunol; 2016 Nov; 84(5):255-261. PubMed ID: 27541573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8
    Chen H; Chen Y; Liu H; Que Y; Zhang X; Zheng F
    Front Immunol; 2018; 9():1179. PubMed ID: 29896199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Emerging Role of Myeloid-Derived Suppressor Cells in Tuberculosis.
    Magcwebeba T; Dorhoi A; du Plessis N
    Front Immunol; 2019; 10():917. PubMed ID: 31114578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of plasma amino acid profile-based index and CA125 in the diagnosis of epithelial ovarian cancers and borderline malignant tumors.
    Miyagi E; Maruyama Y; Mogami T; Numazaki R; Ikeda A; Yamamoto H; Hirahara F
    Int J Clin Oncol; 2017 Feb; 22(1):118-125. PubMed ID: 27623814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells.
    Alissafi T; Hatzioannou A; Mintzas K; Barouni RM; Banos A; Sormendi S; Polyzos A; Xilouri M; Wielockx B; Gogas H; Verginis P
    J Clin Invest; 2018 Aug; 128(9):3840-3852. PubMed ID: 29920188
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloid cells as orchestrators of the tumor microenvironment: novel targets for nanoparticular cancer therapy.
    Tuettenberg A; Steinbrink K; Schuppan D
    Nanomedicine (Lond); 2016 Oct; 11(20):2735-2751. PubMed ID: 27658725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.